GET DAILY SIGNALSJohnson & Johnson (JNJ): Assessing the Potential +16% Upside to $320
Key Takeaways
- The $320 target used here is a publicly discussed bullish objective — most notably UBS's price target — not a calculated analyst consensus.
- The target rests at the high end of the Street's range rather than on an average; the overall mean of roughly two dozen current targets is near $279, barely above the latest price.
- At a recent close of $276.22, reaching $320 would require an upside of about 16%.
- Published price targets span roughly $190 to $320, a wide band that reflects genuine disagreement over valuation and pipeline durability.
- Key supports include new medicine launches, raised 2026 guidance, and improved clarity on talc litigation; key risks include a rich valuation and post-earnings volatility.
- For more information on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated Tickeron pages.
- Readers can also explore Trending AI Robots to see AI-driven trading strategies across the market.
How the $320 Target Came Into View
Because the stock's average analyst price target sits only about 1% above the latest price, a conventional "average analyst target" headline would be meaningless. The $320 level instead reflects an objective that is actually being discussed in public research. UBS analyst Michael Yee reiterated a Buy rating with a $320 target in late October 2026, and $320 has repeatedly appeared as the high end of the aggregated Street range tracked by S&P Global and MarketBeat.
For context, roughly 23 to 26 analysts currently cover JNJ. Their targets run from about $190 on the low end to $320 on the high end, with an overall mean near $279 (S&P Global puts the figure at about $279, MarketBeat at roughly $276). The consensus rating is generally described as "Buy" or "Moderate Buy." That spread — nearly $130 between the lowest and highest targets — shows that bullish and cautious analysts disagree sharply about how much the recent re-rating should persist. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The shares recently closed at $276.22, within about 2% of a 52-week high near $282 and far above the 52-week low of about $185. Reaching $320 would require a move of roughly 16%, which is a substantial advance from current levels. The path would most likely depend on sustained execution of the company's new-medicine cycle rather than further multiple expansion alone. JNJ's trailing P/E (price-to-earnings ratio) now sits near 42, a rich level for a diversified healthcare name, though the forward multiple is considerably lower, around 23.
What Could Support a Move Toward the Target
Several fundamentals underpin the bullish case. The company has raised full-year guidance, and analysts have cited momentum from newer products in both the pharmaceutical and MedTech businesses. Clarity around talc litigation exposure has also reduced a long-standing overhang. A defensive cash-generative profile, a dividend yield near 2%, and a series of 2026 target increases — including a boost to $320 in September and new $300-plus targets from firms such as Erste Group — reflect improving sentiment. If new medicines continue to ramp and margins hold, the earnings foundation could support a higher valuation over time.
What Could Prevent the Target From Being Reached
The principal obstacle is valuation. A trailing P/E near 42 leaves limited room for error, and any earnings disappointment or growth slowdown could trigger multiple compression. Notably, JNJ's shares fell roughly 6% after what RBC Capital called "in-line" third-quarter results that included raised guidance — a decline the firm characterized as excessive but which underscored how crowded and volatile the position has become. Drug-pricing policy risk, patent expirations, competition in key therapy areas, and the possibility of sector rotation away from healthcare all represent additional headwinds.
Technical Levels and Market Structure
The shares are trading just under a 52-week high near $282, which now functions as the nearest resistance level. A decisive move through that zone would open the door toward the psychologically significant $300 mark and, beyond it, the $320 objective. On the downside, the prior consolidation area in the mid-$260s to low $270s and the psychologically important $250 level are the most relevant support zones to watch. The long-term uptrend from the $185 low remains intact but has steepened, leaving the stock technically extended. From what I see, the AI Pattern Search Engine can help identify similar setups in comparable names.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms vary. Investors weighing the $320 objective should watch the next quarterly earnings report, scheduled for late January 2027, along with any further guidance revisions and analyst target changes. New-product launch data, margin trends, regulatory developments on drug pricing, and any shift in the stock's crowded positioning are the most relevant near-term signals.
Final Assessment
The $320 objective for Johnson & Johnson is a substantial, roughly 16% step above the current price, and it is best understood as a bullish public-discussion target — anchored by UBS's published figure and the high end of the Street's $190-to-$320 range — rather than a consensus expectation. The average analyst target of roughly $279 implies far less upside and reflects the wide disagreement between bulls citing new-medicine momentum and skeptics focused on a rich valuation. Whether the stock reaches $320 will depend on continued pipeline execution, margin discipline, and the market's willingness to sustain an elevated multiple. Investors should monitor earnings, guidance, analyst revisions, and the $282 breakout zone rather than treat any single number as a foregone conclusion.
AI Daily Buy/Sell Signals
I’ve found Tickeron’s AI Daily Buy/Sell Signals helpful for tracking names like JNJ that have moved sharply and now sit near key resistance. The tool applies artificial intelligence to monitor thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals based on technical behavior and shifting market conditions. It supports a more structured way to review entries, exits, and trend changes without relying solely on manual analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
JNJ in upward trend: 10-day moving average broke above 50-day moving average on October 30, 2026
The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where JNJ's RSI Indicator exited the oversold zone, 17 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 59%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 38 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 45%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 19 of 47 cases over the following month. The odds of a continued upward trend are 40%.
JNJ moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 163 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 62 cases where JNJ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.834) is normal, around the industry mean (-1.360). P/E Ratio (31.640) is within average values for comparable stocks, (21.695). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.038) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
Advertisement